HB-200 arenavirus-based immunotherapy plus pembrolizumab as first-line treatment of patients with recurrent/metastatic HPV16-positive head and neck cancer: Updated results Meeting Abstract
| Authors: | Ho, A. L.; Nabell, L.; Neupane, P. C.; Posner, M. R.; Yilmaz, E.; Niu, J.; Naqash, A. R.; Pearson, A. T.; Wong, S. J.; Nieva, J. J.; Laux, D. E.; Wong, D. J. L.; Li, Z.; Rosenberg, A. J.; Wong, W.; Qing, X.; Iacobucci, C.; Lauterbach, H.; Tchakov, I.; Pfister, D. G. |
| Abstract Title: | HB-200 arenavirus-based immunotherapy plus pembrolizumab as first-line treatment of patients with recurrent/metastatic HPV16-positive head and neck cancer: Updated results |
| Meeting Title: | 2024 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2024 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-06-01 |
| Language: | English |
| ACCESSION: | WOS:001275557401470 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2024.42.16_suppl.6005 |
| Notes: | Meeting Abstract: 6005 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
